Business : AGC Biologics To Support Teikoku Seiyaku Lumbar Disc Herniation Therapy Development

KUALA LUMPUR, May 26 (Bernama) -- AGC Biologics has been selected by Teikoku Seiyaku Co Ltd to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7) therapy being developed to treat lumbar disc herniation.

Go to News Site